Faculty from a recent Institutional Perspectives in Cancer webinar on gastrointestinal cancer hosted by the University of Kentucky discuss the current paradigms in hepatocellular carcinoma, colorectal cancer, and pancreatic cancer.
Welcome to OncLive On Air™! I’m your host today, Jessica Hergert.
OncLive On Air™ is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, we had the pleasure of speaking with the faculty of a recent Institutional Perspectives in Cancer webinar on gastrointestinal cancers hosted by the University of Kentucky.
At the meeting, faculty discussed the current paradigms in hepatocellular carcinoma (HCC), colorectal cancer (CRC), and pancreatic cancer.
First, we spoke with the chair of the meeting, Joseph Kim, MD, professor of surgery and chief in the Division of Surgical Oncology at the University of Kentucky Markey Cancer Center. Listen on to hear Kim discuss the management of advanced HCC.
Next, Michael J. Cavnar, MD, assistant professor of surgery at the University of Kentucky Markey Cancer Center, stopped by. Listen on to hear Cavnar discuss the factors that inform treatment interventions for patients with left- versus right-sided CRC, multidisciplinary treatment strategies, current approaches for managing liver metastases, and more.
We were then joined by Prakash Pandalai, MD, assistant professor of surgery and surgical oncologist at the University of Kentucky, Markey Cancer Center. Listen on to hear Pandalai discuss the development and management of peritoneal carcinomatosis in CRC.
We closed out the night with Reema Patel, MD, associate program director of the Hematology & Medical Oncology Fellowship and assistant professor of medicine in the Division of Medical Oncology at the University of Kentucky. Listen on to hear Patel discuss the importance of the NAPOLI trials and emerging agents coming down the pike in pancreatic cancer.